Clinical Trials
348
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (238 trials with phase data)• Click on a phase to view related trials
Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer
- Conditions
- Radiation Dermatitis
- Interventions
- Drug: ROS-scavenging NanoenzymesBehavioral: Standard of care
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07064577
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- Conditions
- PD-1 mRNA LNP VaccinePrimary Liver Cancer
- Interventions
- Drug: Low Dose PD-1 mRNA LNP VaccineDrug: Medium dose PD-1 mRNA LNP vaccinesDrug: High dose PD-1 mRNA LNP vaccines
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT07053072
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Efficacy and Safety of Contrast EUS-Guided Tissue Glue/Coil Devascularization vs. BRTO for Preventing Recurrent Gastric Variceal Bleeding
- Conditions
- Gastric Varices Bleeding
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 242
- Registration Number
- NCT07049146
- Locations
- 🇨🇳
37 Guoxue Lane, Chengdu, Sichuan, China
Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors
- Conditions
- Radiation-induced Oral Mucositis
- Interventions
- Drug: Spray of placeboDrug: Spray of spirulina derivativesRadiation: Radiotherapy
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT07040969
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
- Conditions
- Head and Neck Squamous Cell CarcinomaLow-dose RadiotherapyImmunotherapyTargeted Therapy
- Interventions
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT07040956
- Locations
- 🇨🇳
Department of Radiation Oncology, Chengdu, Sichuan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 69
- Next
News
Neoadjuvant Immunochemotherapy Shows Promising Results in Locally Advanced Oral Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy with camrelizumab plus nab-paclitaxel and cisplatin demonstrated a favorable pathological response in patients with locally advanced oral squamous cell carcinoma, achieving a 69% major pathological response rate and 41.4% pathological complete response rate.
ICG-HSA Complex Enhances Fluorescence Imaging in Laparoscopic Liver Resection: A Randomized Controlled Trial
A prospective, double-blind, randomized controlled trial is underway to evaluate a novel indocyanine green–human serum albumin (ICG-HSA) complex for fluorescence-guided laparoscopic anatomical liver resection (LALR).
Secukinumab and Adalimumab Show Distinct Benefits in Psoriatic Arthritis Treatment
A recent study comparing secukinumab and adalimumab for psoriatic arthritis (PsA) found both effective, but with distinct advantages.